ArticleBioinformation2023
Interleukin-6 and uric acid among type 2 diabetes mellitus patients with coronary artery disease.
Article in Bioinformation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The type 2 diabetes mellitus is considering as metabolic disorder, the unfavourable long-term outcomes and closely associated with chronic inflammation. The present study investigated to explore the association of interleukin-6 and uric acid in patients with type 2 diabetes mellitus and coronary artery disease. Newly diagnosed CAD patients with T2DM (100) and T2DM and CAD patients after 5 years (100) underwent detailed anthropometric, demographic, biochemical and experimental characterization. The serum levels of interleukin 6 were measured by enzyme linked immuno-sorbent assay. The T2DM and CAD patients after 5 years had significant higher circulating levels of interleukin 6 and significant decreased levels of uric acid. The newly diagnosed CAD patients with T2DM had significant higher circulating levels of interleukin 6. Significant positive correlation was found between fat mass and IL-6, and negative correlation with uric acid and IL-6, (P<0.05). The both the groups of T2DM with CAD patients shown significantly elevated levels of interleukin 6, based on this findings interleukin 6 might be used as early predictable and prognostic marker for CAD in patients with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.